Related Experiment Videos
[Results of immunosuppressive therapy of chronic glomerulonephritis in 400 patients]
Insights
Immunosuppressive therapy for chronic glomerulonephritis shows a 6.9% rate of terminal renal insufficiency. Treatment complications occurred in 26% of patients, necessitating therapy recommendations.
Area of Science:
- Nephrology
- Immunology
- Internal Medicine
Context:
- Chronic glomerulonephritis (CGN) management requires effective immunosuppressive therapy.
- Assessing treatment success involves evaluating renal function and clinical markers.
- Long-term outcomes and complications of immunosuppression in CGN are critical.
Purpose:
- To evaluate the efficacy and safety of immunosuppressive therapy in chronic glomerulonephritis.
- To identify predictors of treatment success and failure.
- To formulate evidence-based recommendations for CGN management.
Summary:
- This study analyzed 400 patients with chronic glomerulonephritis undergoing immunosuppressive therapy for an average of 31.9 months.
- Renal function (serum creatinine), proteinuria, nephrotic syndrome, and hypertension were assessed alongside histological findings.
- A significant portion (26.8%) had initial renal insufficiency, and 6.9% developed end-stage renal disease. Therapy-related complications were noted in 26% of patients.
Impact:
- Provides insights into the long-term outcomes of immunosuppressive therapy for chronic glomerulonephritis.
- Highlights the incidence of renal insufficiency and treatment complications, informing clinical practice.
- Contributes to the development of improved therapeutic strategies and patient management guidelines for CGN.
Abstract:
For the judgment of the success of the immunosuppressive therapy of chronic glomerulonephritis 400 patients (242 males and 158 females) at an average age of 31.2 years were examined after an average duration of treatment of 31.9 months. Apart from the renal function (serum creatinine), the histological and immunohistological form of the glomerulonephritis for the valuation further clinico-paraclinical data were taken into consideration: proteinuria, nephrotic syndrome, arterial hypertension and the combination of nephrotic syndrome and arterial hypertension. At the beginning of the treatment 293 of 400 patients (73.2%) had a normal renal function, 107 of 400 patients (26.8%) were initially renal-insufficient. 16 of 400 patients (4.0%) had additionally a pyelonephritis and 12 of 400 patients (3.0%) had a lupus nephritis. 27 of 400 patients (6.9%) developed a terminal renal insufficiency after an average duration of observation of 40.5 months. Complications caused by therapy were registered in 104 of 400 patients (26.0%). Recommendations for the present therapy of chronic glomerulonephritis are formulated.